Thinly traded nano cap Genocea Biosciences (NASDAQ:GNCA) is up 3% premarket on increased volume (~30K shares) on the heels of its announcement that the Journal of Clinical Oncology has selected its presentation of Phase 1/2a results on investigational neoantigen vaccine GEN-009 as a top 10 featured abstract at ASCO in Chicago. The data will be presented tomorrow.
Management will host a conference call on Monday, June 3, at 8:30 am ET to discuss the data.
#ASCO19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.